Research programme: apoptosis/autophagic cell death stimulants - CleveXel Pharma/Satt Sud Est

Drug Profile

Research programme: apoptosis/autophagic cell death stimulants - CleveXel Pharma/Satt Sud Est

Alternative Names: #236; CVXL-0056

Latest Information Update: 14 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer CleveXel Pharma; SATT Sud Est
  • Class Nucleosides; Triazoles
  • Mechanism of Action Apoptosis stimulants; Autophagy stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Myelodysplastic syndromes
  • Research Acute myeloid leukaemia

Most Recent Events

  • 31 Dec 2013 Early research in Acute myeloid leukaemia in France (PO)
  • 31 Dec 2013 Preclinical trials in Myelodysplastic syndromes in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top